Trials show that a personalized therapy for aggressive brain cancer shows good results
Visit: Alibaba Cloud 6.18 Main Venue: Explosive products will be sold for a limited time at 10 o’clock every day
Lisavanbulin is one of several new drugs currently being developed to inhibit tumor growth and treat this devastating cancer.
Long-term data from a recently completed Phase 1 human trial initially showed mixed results-only 2 out of 20 patients showed significant improvement. However, after carefully reviewing the data, the researchers found that these two successful cases have a common feature.
Researchers found that the tumor tissues of these two patients have high expression of a special protein called EB1. In early trials, 3 out of 20 subjects showed strong EB1 expression.
“EB1 plays a key role in the regulation of microtubule dynamics during cell division, and has also been shown to interact with microtubule-targeted drugs and inhibit tumor growth.” Basilea said.
Preclinical studies have also found that EB1 positive is a strong predictor of efficacy. Based on these findings, a phase 2 trial is currently underway for patients with EB1-positive glioblastoma.
Juanita Lopez of the Institute of Cancer Research said: “We are in a new era of personalized medicine. The markers in cancer cells provide important clues for the treatment of individual diseases. An encouraging early study showed that some patients with EB1-positive advanced brain cancer can be treated with lisavanbulin, a targeted drug that can stop the growth of cancer cells.”
In the recent United States The new findings presented at the annual meeting of the Society of Clinical Oncology (ASCO) showed that EB1 expression can be found in about 5% of glioblastoma cases. The study also observed EB1 expression in some other cancer samples, and found that EB1 expression levels were low in some metastatic melanoma, lung cancer and breast cancer tissues.
Marc Engelhardt, Chief Medical Officer of Brasilia, pointed out: “We are looking forward to the interim results of our Phase 2 study, which enrolls patients with EB1-positive recurrent glioblastoma, which is close to the end of 2021. The clinical proof-of-concept of glioblastoma is based on positive interim results and will support the exploration of patient options based on other tumor types that are EB1 positive, such as melanoma, breast cancer, colorectal cancer and lung cancer or rare cancer types like nerves Angiocytoma or neuroblastoma.”
Paul Nicholson–a patient in an early trial–was discovered that his cancer cells shrank by more than 80%. Three years later, his scan was still positive.
Lopez pointed out that this novel targeted therapy may not be effective for all glioblastoma patients, but it can bring new hope to EB1-positive cancer patients. The preliminary results of the international phase II clinical trial are expected to be announced later this year.
Lopez said: “We believe that our discovery may be a key step in the development of the world’s first targeted brain cancer treatment, and it brings hope to some patients with aggressive glioblastoma. At present, the survival rate of brain cancer patients is very low and there is a lack of treatment options. Therefore, for our limited treatment methods, this may be a very welcome supplement.”